Pharmacokinetics of Deramciclane in Dogs

@article{Bojti1997PharmacokineticsOD,
  title={Pharmacokinetics of Deramciclane in Dogs},
  author={Erzs{\'e}bet Bojti and J{\'a}nos Leibinger and Gy. Gr{\'e}zal and Imre Klebovich},
  journal={Pharmacy and Pharmacology Communications},
  year={1997},
  volume={3},
  pages={503-506}
}
The pharmacokinetic properties of deramciclane fumarate (EGIS-3886; (1R,2S,4R)-(–)-N,N-dimethyl-2-[(1,7,7-trimethyl-2-phenylbicyclo-[2,2,1]-hept-2-yl)oxy]ethanamine-2-(E)-butendioate (1 : 1)), a new potential anxiolytic agent, were investigated in Beagle dogs after 0·5 and 3.0 mg kg−1 single oral doses. Plasma levels of deramciclane were determined by a highly sensitive, validated gas chromatograpic-nitrogen selective detection (GC-NPD) method using a solid-phase extraction (SPE) technique… Expand
1 Citations
Pharmacokinetics of Deramciclane, a Novel Anxiolytic Agent, after Intravenous and Oral Administration
TLDR
After intravenous administration, the pharmacokinetic parameters of deramciclane are adequately described by a three-compartment model and its oral bioavailability is large and uniform enough to allow its clinical use as tablets. Expand